Unique challenges and opportunities in global health to be presented at BIO CEO & Investor Conference
WASHINGTON, D.C. (February 10, 2006) -- BIO Ventures for Global Health (BVGH) will present a panel at the Biotechnology Industry Organization (BIO) CEO & Investor Conference focusing on the role of the biotechnology industry in developing new products for global health.
The session, “What Biotech Brings to the Global Health Puzzle,” will take place on February 14, 2006, from 2-3:30 PM at the Waldorf=Astoria in New York City. Moderated by Christopher D. Earl, PhD, President & CEO, BIO Ventures for Global Health, the panel will feature four industry thought leaders including Dr. Karen Bernstein, Chairman & Editor-in-Chief, BioCentury; Dr. Joshua Boger, Chairman, President & CEO, Vertex Pharmaceuticals; Alexis Borisy, President, CEO & Founder, CombinatoRx; and Osagie O. Imasogie, Senior Managing Partner, Phoenix IP Ventures.
“BVGH is harnessing the innovative capabilities of the biotech industry to devise new solutions for developing world diseases,” stated Dr. Earl. “Our panelists will provide considerable insight into biotech’s role in developing new products for global health.”
The session will draw out specific examples of the meaningful ways that biotech companies can address global health and translate these answers into messages easily understood by those outside the community. The panel will also address the benefits that companies stand to gain by venturing into developing world markets.
More than 2,000 companies, institutional investors, money managers and analysts are expected to attend the BIO CEO and Investor Conference. In its eighth year, the conference is aimed at fueling continued industry growth and investments, and educating new investors on biotechnology’s value, risks and rewards. Up-to-date program information can be found at: http://ceo.bio.org/opencms/ceo/2006/index.jsp.
Media registration will be available onsite starting Monday, February 13, 2006 from 4-7 PM in the Waldorf=Astoria’s Hilton Room. Only reporters and editors working full-time for print or broadcast news organizations may register onsite with valid media credentials.
BIO Ventures for Global Health (BVGH) is breaking down barriers that hinder the development of new vaccines, drugs and diagnostics to treat the urgent medical needs of the developing world. Working globally with partners in the for-profit and non-profit sectors, BVGH is building market-based solutions to catalyze industry investment in global health innovations. With support from the Bill & Melinda Gates and Rockefeller Foundations, BVGH devotes its expertise in the business and science of biotechnology product development to improving the lives of people in the neediest regions of the world.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
###